GRCEGrace Therapeutics Inc.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. (Grace or the Company) (NASDAQ: GRCE) for violations of the securities laws.The investigation focuses on whether the Company issued false...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace...

Earlier this week, the FDA refused to approve Grace Therapeutics’s experimental drug for the treatment of a severe form of acute brain injury.

Grace Therapeutics was seeking FDA approval for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage.

The FDA set a Prescription Drug User Fee Act target action date of April 23 to rule on GTx-104, a potential treatment for patients with aneurysmal subarachnoid hemorrhage.

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling...

Grace Therapeutics, Inc. (NASDAQ:GRCE - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling...

Grace Therapeutics (NASDAQ:GRCE - Get Free Report) posted its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus...